Straight answers
Ipamorelin FAQ
The real questions people ask about Ipamorelin — answered directly, with a citation wherever there's a number.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved, marketed drug, so it isn't being "discontinued" in the usual sense — its clinical development simply stopped. The only published Phase 2 trial (114 bowel-resection patients, 0.03 mg/kg IV twice daily) missed its primary endpoint: time to first tolerated meal was 25.3 h versus 32.6 h on placebo (p=0.15) [3]. With efficacy unproven, no further trials followed.
Will I gain weight on ipamorelin?
There's no human trial answering this, and this site gives no personal predictions. Mechanistically the signal cuts toward weight gain: in mice, two weeks of ipamorelin raised body weight ~15% and elevated fat-pad weight and leptin even without growth hormone [17], and the ghrelin-receptor class activates appetite centers [18]. Any individual outcome is unpredictable and entangled with diet and training.
Does ipamorelin help with gut motility?
In animals, yes — that's its best-studied effect. Rat studies showed ipamorelin accelerated gastric emptying and increased stool output and food intake in post-surgical ileus models [9][10]. But the one human trial built on that rationale missed its goal [3], so "helps gut motility" is well-supported in rodents and unproven in people.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that activates the ghrelin / GHS-R1a receptor to release a clean pulse of growth hormone — without raising cortisol or prolactin even at doses 200-fold above its GH dose [1]. It's the first highly GH-selective growth hormone secretagogue, and it is not an approved drug.
What does ipamorelin do for you?
In the research, ipamorelin releases growth hormone selectively [1] and, via the same ghrelin receptor, signals the gut to move [9][10]. "For you" is the wrong frame, though: there's no proven human benefit. The one human efficacy trial missed its endpoint [3], and popular benefits like sleep and recovery are anecdotal, not clinical findings.
What is ipamorelin peptide?
It's the same thing as ipamorelin — a synthetic pentapeptide and selective growth hormone secretagogue that mimics the hunger hormone ghrelin at the GHS-R1a receptor [1]. "Peptide" just names what kind of molecule it is: a short chain of amino acids, here only five long, designed to resist enzymatic breakdown.
What are the risks of ipamorelin?
The honest answer is that long-term human risk is uncharacterized — no Phase 3, no long safety database [3]. Documented concerns are mechanistic or class-level: a chronic heart-muscle signal in rats from a related ghrelin-receptor compound [6], theoretical IGF-1-and-cancer concerns [1], and blood-sugar effects from a direct pancreatic action [16]. See the cited cautions on Ipamorelin effects.
Does ipamorelin reduce belly fat?
No human trial shows ipamorelin reduces belly fat. The closest recent data is a 2024 ferret study where ipamorelin (1–3 mg/kg) blunted chemotherapy-induced weight loss by ~24% — the opposite context [5]. Mechanistically it even stimulates fat tissue and appetite in mice [17], so a clean "burns belly fat" claim isn't supported by the evidence.
What are the downsides of ipamorelin?
On the reported side (anecdotal): facial flushing, increased hunger, tingling, mild water retention, and grogginess after a dose. On the cited side: unproven human efficacy [3], a class-level cardiac signal [6], and unpredictable glucose effects [16]. The biggest downside is simply how thin the human evidence is. Full breakdown on Ipamorelin effects.
What does CJC-1295 and ipamorelin do?
Together they're meant to raise growth hormone through two different receptors at once: ipamorelin flips the ghrelin receptor [1] while CJC-1295 (a long-acting GHRH analog) flips the GHRH receptor. The pairing is mechanistically logical, but no published trial has tested the combination for any outcome — the rationale rests on each drug's separate pharmacology.
Does ipamorelin increase IGF-1?
Not reliably in short studies. Ipamorelin pulses growth hormone, which can feed liver IGF-1 — but several rodent studies found no measurable rise in total IGF-1 despite clear GH and skeletal effects [4]. That suggests some of ipamorelin's actions are local or pulse-driven rather than showing up as a systemic IGF-1 increase.
How does CJC-1295 ipamorelin work?
Two switches, one goal. Ipamorelin activates the ghrelin/GHS-R1a receptor on pituitary and gut cells [1][9], releasing a pulse of growth hormone cleanly [1]. CJC-1295 activates the separate GHRH receptor and acts long-acting. Combined, the idea is a bigger, more natural GH release from hitting both pathways — though the combination itself is untested in trials.
How much CJC-1295 ipamorelin should I take?
This site doesn't provide doses, and no controlled human trial has established one for the combination. The doses that circulate online are community conventions, not study results [3]. The only ipamorelin amounts with published grounding are the study doses given IV to volunteers and animals under research conditions [2]. See Ipamorelin dosage.
Does CJC-1295 ipamorelin work?
For raising growth hormone short-term, the single-agent pharmacology of each is real [1][2]. For any actual outcome — sleep, fat loss, recovery — the combination has never been tested in a published trial, and ipamorelin's one human efficacy trial missed its endpoint [3]. So "works" is supported for mechanism, unproven for benefits.
How to reconstitute CJC-1295 ipamorelin 5mg?
In research-supply handling, ipamorelin ships as a lyophilized (freeze-dried) powder and is mixed with bacteriostatic water; as a peptide it's kept refrigerated and protected from freeze-thaw [2]. These are general lab-handling notes, not a human-use preparation instruction, and this site offers no step-by-step protocol. See Ipamorelin dosage for the study-grounded kinetics.
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin's terminal half-life is about 2 hours after IV dosing, with clearance 0.078 L/h/kg [2]. The growth-hormone pulse it triggers peaks around 40 minutes post-dose and is a single discrete spike [2]. So the peptide itself clears within hours, though it's also detectable in urine by anti-doping labs.
Does ipamorelin make you hungry?
It can, mechanistically — it activates the ghrelin (hunger-hormone) receptor, and that receptor class drives feeding in animals [18][17]. Community reports describe increased hunger as milder than with GHRP-6 (anecdotal). There's no human appetite trial, but the mechanism makes appetite a real and expected effect. Full deep dive: does ipamorelin make you hungry.
Does ipamorelin increase appetite?
By mechanism, yes. Ghrelin-receptor agonists activate the brain's appetite centers and induce feeding [18], and ipamorelin stimulated fat tissue, leptin, and weight gain in mice independent of growth hormone [17]. How strongly any person notices it varies, and no controlled human appetite study exists — but the appetite signal is built into the receptor it targets.
What does ipamorelin peptide do?
It selectively releases growth hormone by activating the ghrelin/GHS-R1a receptor [1], and through that same receptor it signals the gut to move, accelerating gastric emptying in animal studies [9][10]. It does this without the cortisol and prolactin spillover of older peptides [1]. What it does not have is a proven human benefit — its one efficacy trial missed its goal [3].
How long does it take for ipamorelin to work?
Pharmacologically it acts fast: the growth-hormone pulse peaks about 40 minutes after an IV dose in humans [2]. "Working" in the sense of producing the benefits people seek is a different question with no controlled-trial answer — anecdotal reports of sleep changes often appear within a week or two, but those are stories, not measured findings.
Does ipamorelin cause water retention?
Mild water retention is reported anecdotally, especially in the first few weeks, and described as milder than with older GHRP compounds. There's a plausible basis: growth-hormone excess is linked to sodium and water retention. But the only controlled human trial (a short perioperative window) showed no ipamorelin-specific safety signal [3], so this rests on mechanism and community reports, not a measured finding.
Where to inject CJC-1295 ipamorelin?
This site doesn't give injection instructions or protocols. For context only: in research, the dominant route for ipamorelin is subcutaneous (under the skin), with IV used in human PK and clinical studies and intraperitoneal used in rodent work [2][9]. None of that is human-use guidance — it's a description of how studies administered the compound.